Torii Pharmaceutical Co Ltd (4551.T)
Latest Key Developments (Source: Significant Developments)
Menlo Therapeutics signs license agreement with Japan Tobacco, Torii Pharma for NK-1 receptor antagonist
Menlo Therapeutics Inc : Menlo Therapeutics signs exclusive license agreement with Japan Tobacco and Torii Pharmaceuticals for development and commercialization of NK-1 receptor antagonist in Japan . Entered into license agreement with Japan Tobacco Inc. and Torii Pharmaceutical for development,commercialization of serlopitant in Japan .JT,Torii to pay co upfront licensing fees,payments upon achievement of certain milestones, royalties based on future sales in Japan. Full Article
TOKYO, Jan 23 Japan's Nikkei share average on Tuesday ended at its highest in more than 26 years, with real estate and precision machinery stocks leading the gains.